Factors associated with variation in estimates of the cost of resistant infections

Medical Care

Volumn 48, Issue 9, 2010, Pages 767-775

  Cohen, Bevin ^a   Larson, Elaine L ^a   Stone, Patricia W ^a   Neidell, Matthew ^b   Glied, Sherry A ^b  

^a NewYork Presbyterian Hospital   (United States)

^b Columbia University ^*  (United States)

Author keywords

antibiotic resistance; hospital costs; length of stay

Indexed keywords

ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BLOODSTREAM INFECTION; CONTROLLED STUDY; ENTEROBACTERIACEAE INFECTION; ENTEROCOCCAL INFECTION; HEALTH CARE COST; HUMAN; INFECTION; LENGTH OF STAY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; STAPHYLOCOCCUS INFECTION;

DRUG RESISTANCE, MICROBIAL; HOSPITAL COSTS; HUMANS; INFECTION; LENGTH OF STAY; LINEAR MODELS;

EID: 77955982258     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181e358b9     Document Type: Article

References (50)

1. Rosenthal VD, Maki DG, Mehta A, et al. International Nosocomial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control. 2008;36:627-637.
2. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: A meta-analysis. Infect Control Hosp Epidemiol. 2003;24: 690-698.
3. Lodise TP, McKinnon PS. Burden of methicillin-resistant Staphylococ-cus aureus: Focus on clinical and economic outcomes. Pharmacother-apy. 2007;27:1001-1012.
4. Perencevich EN, Stone PW, Wright SB, et al. Raising standards while watching the bottom line: Making a business case for infection control. Infect Control Hosp Epidemiol. 2007;28:1121-1133.
5. Pelz RK, Lipsett PA, Swoboda SM, et al. Vancomycin-sensitive and vancomycin-resistant enterococcal infections in the ICU: Attributable costs and outcomes. Intensive Care Med. 2002;28:692-697.
6. Lipsky BA, Weigelt JA, Gupta V, et al. Skin, soft tissue, bone, and joint infections in hospitalized patients: Epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol. 2007; 28:1290-1298.
7. Carmeli Y, Triollet N, Karchmer AW, et al. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med. 1999;159:1127-1132.
8. Quach C, Weiss K, Moore D, et al. Clinical aspects and cost of invasive Streptococcus pneumoniae infections in children: Resistant vs. susceptible strains. Int J Antimicrob Agents. 2002;20:113-118.
9. Weigelt JA, Lipsky BA, Tabak YP, et al. Surgical site infections: causative pathogens and associated outcomes. Am J Infect Control. 2010;38:112-120.
10. Capitano B, Leshem OA, Nightingale CH, et al. Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. Am Geriatr Soc. 2003;51:10-16.
11. Shorr AF, Tabak YP, Gupta V, et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10:R97.
12. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis. 1999;5:9-17.
13. Kopp BJ, Nix DE, Armstrong EP. Clinical and economic analysis of methicillin-susceptible and-resistant Staphylococcus aureus infections. Ann Pharmacother. 2004;38:1377-1382.
14. Cosgrove SE, Qi Y, Kaye KS, et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay and hospital charges. Infect Control Hosp Epidemiol. 2005;26:166-174.
15. Paladino JA, Adelman MH, Schentag JJ, et al. Direct costs in patients hospitalized with community-acquired pneumonia after non-response to outpatient treatment with macrolide antibacterials in the US. Pharmaco-economics. 2007;25:677-683.
16. Lee NY, Lee HC, Ko YN, et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bactere-mia. Infect Control Hosp Epidemiol. 2007;28:713-719.
17. Resch A, Wilke M, Fink C. The cost of resistance: Incremental cost of methicillin-resistant Staphylococcus aureus (MRSA) in German hospitals. Eur J Health Econ. 2009;10:287-297.
18. Vandijck DM, Blot SI, Decruyenaere JM, et al. Costs and length of stay associated with antimicrobial resistance in acute kidney injury patients with bloodstream infection. Acta Clin Belg. 2008;63:31-38.
19. Watters K, O'Dwyer TP, Rowley H. Cost and morbidity of MRSA In head and neck cancer patients: what are the consequences? J Laryngol Otol. 2004;18:694-699.
20. Chaix C, Durand-Zaleski I, Alberti C, et al. Control of endemic methi-cillin-resistant Staphylococcus aureus: A cost benefit analysis in an intensive care unit. JAMA. 1999;282:1745-1751.
21. Schwaber MJ, Navon-Venezia S, Kaye KS, et al. Clinical and economic impact of bacteremia with extended-spectrum-/3-lactamase-producing enterobacteriaceae. Antimicrob Agents Chemother. 2006;50:1257-1262.
22. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2005;52:113-122.
23. Reed SB, Friedman JY, Engemann, et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicil-lin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol. 2005;26:175-183.
24. Montecalvo MA, Jarvis WR, Uman J, et al. Costs and savings associated with infection control measures that reduced transmission of vancomy-cin-resistant enterococci in an endemic setting. Infect Control Hosp Epidemiol. 2001;22:437-442.
25. Bach PB, Malak SF, Jurcic J, et al. Impact of infection by vancomycin-resistant Eneterococcus on survival and resource utilization for patients with leukemia. Infect Control Hosp Epidemiol. 2002;23:471-474.
26. McHugh CG, Riley LW. Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol. 2004;25:425-430.
27. Ben-David D, Novikov I, Mermel LA. Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillin-susceptible S. aureus bloodstream infection? Infect control Hosp Epidemiol. 2009; 30:453-460.
28. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592-598.
29. Maclayton DO, Suda KJ, Coval KA, et al. Case-control study of the relationship between MRSA bacteremia with a vancomycin/ng/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther. 2006;28:1208-1216.
30. Lautenbach E, Synnestvedt M, Weiner MG, et al. Epidemiology and impact of imipenem resistance in Acinetobacter baumannii. Infect Control Hosp Epidemiol. 2009;30:1186-1192.
31. Nixon M, Jackson B, Varghese P, et al. Methicillin-resistant Staphylococcus aureus on orthopaedic wards: Incidence, spread, mortality, cost and control. J Bone Joint Surg. 2006;88:812-817.
32. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: At what costs? Infect Control Hosp Epidemiol. 1999;20:408-411.
33. Carmeli Y, Eliopoulos G, Mozaffari E, et al. Health and economic outcomes of Vancomycin-resistant enterococci. Arch Intern Med. 2002; 162:2223-2228.
34. Lautenbach E, Weiner MG, Nachamkin I, et al. Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol. 2006;27:893-900.
35. Stosor V, Peterson LR, Postelnick M, et al. Enterococcus faecium bacteremia. Arch Intern Med. 1998;158:522-527.
36. Roberts RR, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship. Clin Infect Dis. 2009;49:1175-1184.
37. Song X, Srinivasan A, Plaut D, et al. Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol. 2003;24:251-256.
38. Gearhart M, Martin J, Rudich S, et al. Consequences of vancomycin-resistant Enterococcus in liver transplant recipients: A matched control study. Clin Transplant. 2005;19:711-716.
39. Webb M, Riley LW, Roberts RB. Cost of hospitalization and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis. 2001;33:445-452.
40. Evans HL, Lefrak SN, Lyman J, et al. Cost of Gram-negative resistance. Crit Care Med. 2007;35:89-95.
41. Young LS, Sabel AL, Price CS. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii Infection in a surgical intensive care unit. Infect Control Hosp Epidemiol. 2007;28:1247-1254.
42. Wilson SJ, Knipe CJ, Zieger MJ, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control. 2004;32:342-344.
43. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003;36:1433-1437.
44. Maragakis LL, Perencevich EN, Cosgrove SE. Clinical and economic burden of antimicrobial resistance. Expert Rev Anti Infect Ther. 2008; 6:751-763.
45. Freeman J, McGowan JE Jr. Methodologic issues in hospital epidemiology. III. Investigating the modifying effects of time and severity of underlying illness on estimates of cost of nosocomial infection. Rev Infect Dis. 1984;6:285-300.
46. Lautenbach E, Bilker WB, Brennan PJ. Enterococcal bacteremia: Risk factors for vancomycin resistance and predictors of mortality. Infect Control Hosp Epidemiol. 1999;20:318-323.
47. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococcal bloodstream infections. J Infect Dis. 1995;172:993-1000.
48. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. Available at: http://hcupnet.ahrq.gov/. Accessed January 5, 2009.
49. Scott RD. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/Scott-CostPaper.pdf. Accessed January 5, 2009.
50. Kaye KS, Engemann JJ, Mozaffari E, et al. Reference group choice and antibiotic resistance outcomes. Emerg Infect Dis. 2004;10:1125-1128.